The ALK inhibitors market is expected to drive sustained market growth across the 7MM during the 2026–2036 period due to the growing integration of precision oncology, expanding use of molecular diagnostics to identify ALK rearrangements, and the development of next-generation ALK inhibitors such as Neladalkib (NVL-655) (Nuvalent), TRI-611 (TRIANA Biomedicines), APG-2449 (Ascentage Pharma), and others.
LAS VEGAS, July 23, 2026 /PRNewswire/ — DelveInsight’s ALK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-small cell lung cancer (NSCLC), Anaplastic Large Cell Lymphoma (ALCL), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging ALK inhibitors, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan).
Key Takeaways from the ALK Inhibitors Market Report
- The market size for ALK inhibitors was found to be USD 3 billion in the 7MM in 2025.
- The United States accounted for the largest ALK inhibitor treatment market size, approximately 40% of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The report provides the total potential number of patients in the indications, such as Non-small cell lung cancer (NSCLC), Anaplastic Large Cell Lymphoma (ALCL), and others.
- Among the 7MM, the US accounted for the highest number of total ALK cases with ~11,800 cases in 2025.
- Leading ALK inhibitor companies, such as Nuvalent, TRIANA Biomedicines, Ascentage Pharma, and others, are developing novel ALK inhibitors that can be available in the ALK inhibitors market in the coming years.
- Some of the key ALK inhibitors in clinical trials include Neladalkib (NVL-655), TRI-611, APG-2449, and others.
Discover which ALK drugs will lose patent exclusivity @ https://www.delveinsight.com/report-store/alk-market-forecast
Key Factors Driving the ALK Inhibitors Market
- Rising Incidence of ALK-Positive NSCLC: The rising global incidence of NSCLC, coupled with advancements in diagnostic techniques for detecting ALK rearrangements, is increasing the number of patients eligible for ALK-targeted treatments. Enhanced early and precise diagnosis is further contributing to the growth of the market.
- Growing Focus on CNS Disease Control: Brain metastases frequently occur in patients with ALK-positive NSCLC, driving the need for therapies that provide effective control within the central nervous system. Next-generation ALK inhibitors with sustained intracranial efficacy are increasingly being recognized for their clinical value.
- Rising Adoption of Precision Oncology: The growing shift toward biomarker-driven cancer treatment has significantly increased the use of ALK inhibitors. Routine molecular profiling enables clinicians to identify ALK-positive patients who are most likely to benefit from targeted therapies, improving treatment outcomes.
- Emergence of Novel Pipeline Therapies: A clinical pipeline featuring next-generation ALK inhibitors such as Neladalkib (NVL-655) (Nuvalent), TRI-611 (TRIANA Biomedicines), APG-2449 (Ascentage Pharma), and others, and combination treatment strategies is expected to address acquired resistance and extend treatment duration, creating new commercial opportunities in the market.
Aparna Thakur, an oncology expert at DelveInsight, said that among pipeline therapies, neladalkib is expected to achieve gradual uptake as a next-generation brain-penetrant ALK inhibitor designed to target compound resistance mutations with reduced off-target toxicities. While TRI-611 is expected to remain an emerging investigational candidate with uptake is dependent on future clinical efficacy and safety data.
ALK Inhibitors Market Analysis
- Non-small Cell Lung Cancer (NSCLC) continues to be the leading indication for ALK inhibitors, driving most clinical research and development efforts.
- In contrast, ALK-positive anaplastic large cell lymphoma (ALCL) remains a niche but clinically significant indication, with ongoing studies primarily focused on combination treatment strategies.
- The growing implementation of molecular diagnostics, next-generation sequencing (NGS), and precision medicine is enhancing the detection of ALK-positive patients, enabling wider adoption of ALK-targeted therapies across eligible populations.
- Crizotinib, the first ALK inhibitor approved for ALK-positive NSCLC, laid the groundwork for targeted treatment in this setting. However, its clinical use has gradually diminished as more advanced next-generation ALK inhibitors have demonstrated superior efficacy.
- Later-generation ALK inhibitors, including Alectinib and Lorlatinib, have shown substantial improvements in progression-free survival (PFS) and intracranial disease control compared with first-generation therapies, establishing new standards of care for patients with ALK-positive NSCLC.
- The development pipeline for ALK-positive ALCL remains relatively limited, with most advancements stemming from the evaluation of ALK inhibitors originally developed for NSCLC rather than from lymphoma-specific drug discovery programs.
- The evolving ALK inhibitor landscape features several emerging candidates from companies such as Nuvalent (Neladalkib, NVL-655), Ascentage Pharma (APG-2449), TRIANA Biomedicines (TRI-611), along with additional developers advancing novel ALK-targeted therapies.
Learn more about the fastest growing ALK inhibitor market @ ALK Inhibitors Analysis
ALK Inhibitors Competitive Landscape
Some of the ALK inhibitors under development include Neladalkib (NVL-655) (Nuvalent), TRI-611 (TRIANA Biomedicines), APG-2449 (Ascentage Pharma), and others.
Nuvalent’s Neladalkib is an investigational, brain-penetrant, and highly selective ALK inhibitor developed to overcome resistance associated with first-, second-, and third-generation ALK inhibitors. It is engineered to maintain activity against tumors harboring treatment-emergent single or compound ALK resistance mutations, including the G1202R mutation. Neladalkib has been granted Breakthrough Therapy Designation (BTD) by the US FDA for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have previously received two or more ALK tyrosine kinase inhibitors (TKIs). Additionally, it has received Orphan Drug Designation (ODD) for ALK-positive NSCLC.
TRIANA Biomedicines’ TRI-611 is an investigational oral small-molecule therapy designed to selectively target and degrade ALK fusion proteins in patients with ALK-positive NSCLC, where ALK TKIs represent the current standard of care. As a potent, brain-penetrant molecular glue degrader, TRI-611 promotes the interaction between ALK and cereblon through a distinctive binding mechanism that functions independently of the kinase active site, offering a novel strategy to overcome resistance to conventional ALK-targeted therapies.
Ascentage Pharma’s APG-2449 is a multi-target inhibitor of FAK, ALK, and ROS1 that is currently being evaluated in clinical studies for its potential to overcome resistance driven by tumor microenvironment signaling.
The anticipated launch of these emerging therapies are poised to transform the ALK inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the ALK inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about companies developing ALK inhibitors, visit @ ALK Inhibitors Treatment
Recent Developments in the ALK Inhibitors Market
- In June 2026, GSK plc announced an agreement to acquire Boston-based clinical-stage biopharmaceutical company Nuvalent, Inc. for approximately $10.6 billion. The acquisition aligns with GSK’s strategic focus on strengthening its oncology portfolio by investing in therapies with validated targets that aim to improve efficacy and tolerability compared to current standard-of-care treatments.
- In May 2026, Pfizer shared a 7-year update from the pivotal Phase III (CROWN) study that supports lorlatinib (LORBRENA) as a guideline-recommended first-line treatment for ALK-positive metastatic NSCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- In May 2026, Nuvalent, Inc. announced that the FDA had accepted its New Drug Application (NDA) for neladalkib for review. The agency has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026.
- In May 2026, Nuvalent presented pivotal data for neladalkib, global (ALKOVE-1) Phase I/II clinical trial, in addition to preliminary data for ALKAZAR, during an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
- In March 2026, Ascentage Pharma announced that four abstracts highlighting the latest preclinical results from its pipeline programs had been selected for poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2026. The data to be presented encompasses three of the Company’s novel drug candidates, one of which is FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449.
- In March 2026, TRIANA Biomedicines announced that the US FDA granted Fast Track designation for TRI-611 for the treatment of ALK+ NSCLC.
- In March 2026, TRIANA Biomedicines announced that the first patient had been dosed in a Phase I/II clinical trial evaluating TRI-611 in patients with ALK–positive NSCLC.
- In January 2026, TRIANA Biomedicines announced a research collaboration with Johnson & Johnson to advance the discovery of important molecular glue targets in oncology. The collaboration aims to advance next-generation molecular glue degraders by applying TRIANA’s proprietary molecular glue discovery platform to targets that have been inadequately targeted or considered undruggable.
ALK Inhibitors Epidemiology Segmentation
The ALK inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. In the US, stage-specific NSCLC incident cases were of stage IV (43%), followed by stage I (29%). The ALK inhibitors target patient pool is segmented into:
- Incident Cases of Selected Indications for ALK Inhibitors
- ALK biomarker Positive Patient Pool of ALK Inhibitors
- Stage-specific Incident Cases of Selected Indications for ALK Inhibitors
- Treated Patient Pool in Selected Indications for ALK Inhibitors
|
ALK Inhibitors Report Metrics |
Details |
|
Study Period |
2022–2036 |
|
ALK Inhibitors Report Coverage |
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
|
Key Indications Covered in the Report |
Non-small cell lung cancer (NSCLC), Anaplastic Large Cell Lymphoma (ALCL), and others |
|
ALK Inhibitors Market CAGR |
4 % |
|
ALK Inhibitors Market Size in 2025 |
USD 3 billion |
|
Key ALK Inhibitors Companies |
Nuvalent, TRIANA Biomedicines, Ascentage Pharma, Pfizer, Genentech, Roche, and others |
|
Key ALK Inhibitors |
Neladalkib (NVL-655), TRI-611, APG-2449, LORBRENA, ALECENSA, and others |
Scope of the ALK Inhibitors Market Report
- ALK Inhibitors Patient Population Forecast
- ALK Inhibitors Therapeutics Market Size
- ALK Inhibitors Pipeline Analysis
- ALK Inhibitors Market Size and Trends
- ALK Inhibitors Market Opportunity
- ALK Inhibitors Market Unmet Needs
- KOL’s Views on ALK Inhibitors
- ALK Inhibitors Market Access and Reimbursement
Discover the best emerging ALK inhibitors in pipeline @ ALK Inhibitors Clinical Trials
Table of Contents
|
1 |
ALK Inhibitors Market Key Insights |
|
2 |
ALK Inhibitors Market Report Introduction |
|
3 |
Executive Summary |
|
4 |
Key Events |
|
5 |
Epidemiology and Market Methodology of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
6 |
Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Overview at a Glance |
|
6.1 |
Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA]) |
|
6.2 |
Market Share of Anaplastic Lymphoma Kinase (ALK) Inhibitors By Therapies (%) in the 7MM in 2025 |
|
6.3 |
Market Share of Anaplastic Lymphoma Kinase (ALK) Inhibitors By Therapies (%) in the 7MM in 2036 |
|
7 |
Anaplastic Lymphoma Kinase (ALK) Inhibitors Disease Background And Overview |
|
7.1 |
Introduction |
|
7.2 |
Target Indications |
|
7.3 |
Treatment and Management |
|
8 |
Epidemiology and Patient Population of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
8.1 |
Key Findings |
|
8.2 |
Assumption and Rationale |
|
8.3 |
Total Cases of Selected Indication for Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM |
|
8.4 |
Total Eligible Patient Pool for Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM |
|
8.5 |
Total Treated Cases in Selected Indications Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM |
|
9 |
Marketed Therapies |
|
9.1 |
Marketed Competitive Landscape of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
9.2 |
Lorlatinib (LORBRENA): Pfizer |
|
9.2.1 |
Product Description |
|
9.2.2 |
Regulatory Milestones |
|
9.2.3 |
Other Developmental Activities |
|
9.2.4 |
Summary of Pivotal Trials |
|
9.2.5 |
Analyst Views |
|
9.3 |
Alectinib (ALECENSA): Genentech and Roche |
|
10 |
Emerging Therapies |
|
10.1 |
Emerging Competitive Landscape of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
10.2 |
Neladalkib (NVL-655): Nuvalent |
|
10.2.1 |
Product Description |
|
10.2.2 |
Other Developmental Activities |
|
10.2.3 |
Clinical Development |
|
10.2.3.1 |
Clinical Trial Information |
|
10.2.4 |
Safety and Efficacy |
|
10.2.5 |
Analyst Views |
|
10.3 |
APG-2449: Ascentage Pharma |
|
11 |
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Seven Major Market Analysis |
|
11.1 |
Key Findings |
|
11.2 |
Market Outlook of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
11.3 |
Conjoint Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
11.4 |
Key Market Forecast Assumptions |
|
11.5 |
Total Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM |
|
11.6 |
The United States ALK Inhibitors Market |
|
11.6.1 |
Total Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors in the United States |
|
11.6.2 |
Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapies in the United States |
|
11.7 |
EU4 and the UK ALK Inhibitors Market |
|
11.8 |
Japan ALK Inhibitors Market |
|
12 |
Unmet Needs of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
13 |
SWOT Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
14 |
KOL Views of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
14.1 |
Expert/KOL Interview Highlights |
|
15 |
Market Access and Reimbursement of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
15.1 |
The US |
|
15.2 |
In EU4 and the UK |
|
15.3 |
Japan |
|
15.4 |
Summary and Comparison of Market Accesses and Pricing Policy Developments in 2025 |
|
15.5 |
Market Access and Reimbursement of Anaplastic Lymphoma Kinase (ALK) Inhibitors |
|
16 |
Bibliography |
|
17 |
ALK Inhibitors Market Report Methodology |
Related Reports
ALK mNSCLC Market
ALK mNSCLC Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALK mNSCLC companies, including Xcovery, Nuvalent, and others.
Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including BeiGene, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK and others.
Non-small Cell Lung Cancer Clinical Trial Analysis
Non-small Cell Lung Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including ArriVent BioPharma, iTeos Therapeutics, GSK, Incyte, Macrogenics, AstraZeneca, Hutchison MediPharma, Hoffmann-La Roche, Genentech, AnaptysBio, Shanghai Henlius Biotech, Otsuka Pharmaceutical, Bristol-Myers Squibb, OSE Immunotherapeutics, Arcus Biosciences, Gilead Sciences, Pfizer, Cullinan Oncology, Taiho Pharma, ImmunityBio, Jiangsu Hansoh Pharmaceutical, Daiichi Sankyo, Boehringer Ingelheim, Moderna Therapeutics, Merck Sharp & Dohme, Eli Lilly and Company, BeyondSpring, Immutep, Genmab, Imugene, Dizal Pharmaceutical, Regeneron Pharmaceuticals, AbbVie, Candel Therapeutics, and others.
Anaplastic Large Cell Lymphoma Market
Anaplastic Large Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key ALCL companies, including Takeda Pharmaceutical Company, Bristol Myers Squibb, Merck & Co., F. Hoffmann-La Roche, Novartis, Pfizer, Genmab, ADC Therapeutics, Citius Pharmaceuticals, Affimed, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us:
Shruti Thakur
[email protected]
+14699457679
SOURCE DelveInsight Business Research, LLP
